Please login to the form below

Not currently logged in
Email:
Password:

Kamada

This page shows the latest Kamada news and features for those working in and with pharma, biotech and healthcare.

Shire receives FDA nod for self-infusion of Glassia

Shire receives FDA nod for self-infusion of Glassia

Originally approved in 2010, Shire and partner Kamada's therapy is the only liquid, ready-to-use augmentation product for AAT deficiency currently on the market.

Latest news

  • Biologics buoyant

    52 . Kamada/Baxter. Glassia (liquid Alpha-1 Antitrypsin; AAT) – AAT deficiency (US, Canada, Australia and New Zealand)  . FDA approved. 45. Marina Biotech/Cypress Bioscience. Carbetocin (nasal oxytocin analogue)  - autism.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...